RGEN
Repligen Corp.

1,559
Mkt Cap
$8.04B
Volume
896,249.00
52W High
$182.52
52W Low
$102.97
PE Ratio
5,667.70
RGEN Fundamentals
Price
$145.66
Prev Close
$142.82
Open
$144.40
50D MA
$138.39
Beta
1.52
Avg. Volume
1.16M
EPS (Annual)
-$0.4561
P/B
3.94
Rev/Employee
$356,827.33
Loading...
Loading...
News
all
press releases
Repligen Corporation (NASDAQ:RGEN) Receives Average Rating of "Moderate Buy" from Brokerages
Repligen Corporation (NASDAQ:RGEN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fifteen brokerages that are covering the stock, Marketbeat.com reports. One...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down
Repligen posts strong Q3 results with revenue growth and an earnings beat, yet shares dip as tighter EPS guidance tempers investor optimism.
Zacks·13d ago
News Placeholder
Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates
Repligen (RGEN) delivered earnings and revenue surprises of +9.52% and +4.18%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
News Placeholder
Apellis Pharmaceuticals, Inc. (APLS) Reports Next Week: Wall Street Expects Earnings Growth
Apellis Pharmaceuticals (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·19d ago
News Placeholder
ALKS vs. RGEN: Which Stock Is the Better Value Option?
ALKS vs. RGEN: Which Stock Is the Better Value Option?
Zacks·21d ago
News Placeholder
Earnings Preview: Repligen (RGEN) Q3 Earnings Expected to Decline
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·21d ago
News Placeholder
Do Options Traders Know Something About Repligen Stock We Don't?
Investors need to pay close attention to RGEN stock based on the movements in the options market lately.
Zacks·3mo ago
News Placeholder
Repligen (RGEN) Lags Q2 Earnings Estimates
Repligen (RGEN) delivered earnings and revenue surprises of -7.50% and +3.56%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Here's Why Repligen (RGEN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·4mo ago
News Placeholder
Do Options Traders Know Something About Repligen (RGEN) Stock We Don't?
Zacks·5mo ago

Latest RGEN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.